Analyst Juan C. Sanabria of BMO Capital maintained a Hold rating on Sabra Healthcare REIT, boosting the price target to $23.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Juan C. Sanabria has given his Hold rating due to a combination of factors, including a solid first‑quarter earnings beat driven by strong same‑store NOI growth in the SHOP portfolio, which now accounts for a larger share of Sabra’s overall NOI. He also notes that year‑to‑date investment activity exceeding $400M, including preferred development funding, demonstrates good execution but has not yet translated into higher company guidance, which remains slightly below consensus expectations.
Sanabria also points to emerging risks, such as operational issues at a behavioral health tenant (Landmark) and the sizeable RCA loan maturing in late 2026 at a relatively high interest rate, as areas requiring further clarity. While normalized FAD and FFO modestly outpaced Street estimates and full‑year guidance was reaffirmed, the combination of only incremental upside, ongoing credit and refinancing questions, and an already improved share price supports a neutral, or Hold, stance even as he raises his price target from $22 to $23.
C. Sanabria covers the Real Estate sector, focusing on stocks such as Welltower, Public Storage, and Brixmor Property. According to TipRanks, C. Sanabria has an average return of 2.8% and a 52.16% success rate on recommended stocks.